Home›Companies›Biotech & Pharma›NovAb

NovAb, Inc.

Develops antibodies for potential diagnostic and therapeutic uses.

No LinkedIn page we could confirm. Why?
Updated Nov 10, 2026·Latest SEC filing Apr 16, 2026·Suggest an edit

About NovAb

NovAb is a private company based in Tucker, Georgia. It has reported $1,550,000 raised in nine offerings on Form D since September 2016.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Apr 1, 2026Apr 16, 2026$65,000of $250K target2$32,500Debt, Convertible notesRule 506(b)Form D ↗
Jan 16, 2026Jan 26, 2026$50,000fully sold2$25,000Debt, Convertible notesRule 506(b)Form D ↗
Jul 31, 2025Aug 12, 2025$210,000fully sold2$105KDebt, Convertible notesRule 506(b)Form D ↗
Jan 30, 2025Feb 11, 2025$250,000fully sold3$83,333Debt, Convertible notesRule 506(b)Form D ↗
Jun 30, 2024Jul 12, 2024$125,000fully sold2$62,500Debt, Convertible notesRule 506(b)Form D ↗
Jul 28, 2023Aug 11, 2023$250,000fully sold3$83,333Debt, Convertible notesRule 506(b)Form D ↗
Feb 17, 2023Mar 9, 2023$300,000fully sold3$100KConvertible NotesRule 506(b)Form D ↗
Mar 10, 2022Mar 16, 2022$300,000fully sold5$60,000Convertible NotesRule 506(b)Form D ↗
Not yetSep 30, 2016$0of $600K target0—EquityRule 506(b)Form D ↗
Total, nine offerings$1,550,000

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on NovAb's Form D filed Apr 16, 2026.

GD
Gregory Dane
Director
LC
Lovick Cannon
President and Chairman, Board of Directors
TC

Earlier filings also listed Max Cooper (director, last listed Sep 2016) and L. Cannon (president & ceo, director, last listed Sep 2016).

Sources

  1. SECNovAb, Inc. filing history
  2. InvestorGeorgia Research Alliance portfolio: NovAb